The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
General Updates | Sequencing therapies in R/R DLBCL, MCL & FL: CAR-T, bispecifics, BTK inhibitors & more
In this discussion, leading experts Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, Gloria Iacoboni, MD, PhD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, and Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, take part in an engaging discussion on the sequencing of novel agents in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL), including diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL). They share insights into various agents, such as CAR T-cells, bispecific antibodies, and BTK inhibitors, and provide advice for hematologists. This discussion took place virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
